Growth hormone & endocrine research
Teriparatide (PTH 1-34): Research Overview
The active fragment of parathyroid hormone, approved for osteoporosis and widely studied in bone research.
Also known as PTH (1-34) · Forteo · Forsteo · PTH 1-34
What is Teriparatide?
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation.
What is Teriparatide researched for?
- FDA-approved for women with osteoporosis at high risk of fracture.
- FDA-approved for men with primary or hypogonadal osteoporosis at high risk.
- FDA-approved for men and women with osteoporosis from sustained corticosteroid use.
- Research interest in accelerating fracture healing and bone repair.
- Investigated for jawbone regeneration in dental applications.
How does Teriparatide work?
Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption.
References
Teriparatide StatPearls
2024
Intermittent PTH exposure induces bone formation more than resorption; FDA-approved for osteoporosis.
The effect of teriparatide therapy on bone density in men with osteoporosis PubMed
2002
Spine BMD increased 5.9% (20mcg) and 9.0% (40mcg); femoral neck increased 1.5-2.9%.
Teriparatide: 2.5 Years of
Experience Journal of Bone and Mineral Research · 2006
Reduced vertebral fractures by 65% and nonvertebral fractures by 35% after 20 months.
Parathyroid Hormone (1-84) and Teriparatide in Postmenopausal Osteoporosis Women's Health
2006
Initial formation without resorption creates 'anabolic window' for rapid bone volume increase.
Common questions
Can teriparatide reverse osteoporosis or just slow bone loss?
Teriparatide actively reverses osteoporosis by building new bone, unlike antiresorptive drugs that only slow loss. Clinical trials show 5-9% spine bone density increases and 65% fracture risk reduction - making it uniquely anabolic rather than protective.
How does teriparatide create an 'anabolic window' for bone formation?
Daily intermittent PTH exposure stimulates osteoblasts (bone-forming cells) more strongly than osteoclasts (bone-removing cells), creating a window where formation exceeds resorption. This contrasts with continuous PTH, which causes net bone loss. The daily injection timing is critical to maintain this anabolic advantage.